Pharmaceutical Technology

JULY 8, 2022

Xenetic Biosciences and Catalent Pharma Solutions have signed an agreement for the cGMP manufacturing of the Xenetic’s recombinant protein, Human DNase I. The DNase platform can potentially act on neutrophil extracellular traps (NETs), which are web-like structures made of extracellular chromatin covered with histones and other proteins.

Manufacturing 147

Manufacturing Protein Clinical Development Development 147

Pharmaceutical Technology

APRIL 25, 2023

German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology. 3BP receives an initial payment of $40m, and $425m as development, regulatory and commercial milestone payments.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Roots Analysis

MAY 21, 2024

Proteins are the chains of amino acids linked together in different combinations and perform a wide variety of functions. However, continuous regulation of the cellular proteome is essential for maintaining the right balance of different proteins necessary for normal cellular function, survival, and proliferation.

Protein 40

Protein Marketing Development Antibody 40

Pharmaceutical Technology

MAY 26, 2023

HanAll Biopharma and Daewoong Pharmaceutical will combine their resources and knowledge to develop NurrOn’s ATH-399A and other compounds targeting Nurr1 [nuclear receptor-related 1 protein] to treat neurodegenerative disorders. Nurr1 is a class of proteins important for the development and maintenance of dopamine in the brain.

Development 130

Development Clinical Trials Clinical Trials Protein 130

Pharmaceutical Technology

MAY 9, 2023

FibroGen has signed an exclusive licence agreement with Fortis Therapeutics for the FOR46 antibody-drug conjugate (ADC) that targets a new epitope on CD46, a protein-coding gene. FOR46 is a natural fit with our research and development capabilities and expertise.

Drugs 130

Drugs Clinical Development Antibody Protein 130

Camargo

JULY 27, 2021

When developing a clinical development program for these increasingly popular therapies, it is important that sponsors use modeling and pharmacokinetic (PK) analysis to evaluate parameters that can be measured while dosing with gene therapy drugs, to characterize exposure-response data and inform rational dosing.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

pharmaphorum

DECEMBER 4, 2020

Valneva is paying 30% of development costs and in return Pfizer will pay tiered royalties starting at 19% and will lead late-stage development. VLA15 is the only active Lyme disease vaccine in clinical development today, and covers six strains that are prevalent in North America and Europe.

Vaccine 119

Vaccine Vaccination Bacterium Protein 119

XTalks

NOVEMBER 26, 2024

This progressive disease occurs when misfolded transthyretin (TTR) proteins form amyloid deposits in the heart, leading to cardiac dysfunction. Attruby offers a more potent option , following Pfizer’s tafamidis (Vyndaqel and Vyndamax), the first therapy and TTR stabilizer approved to treat ATTR-CM.

Genetic Disease 105

Genetic Disease Genetics Protein Clinical Development 105

XTalks

DECEMBER 10, 2024

Rilzabrutinib works by targeting BTK, a protein involved in immune cell communication. By inhibiting this protein, the drug disrupts pathways that contribute to platelet destruction and insufficient production. Its selective mechanism aims to minimize off-target effects, making it a potential first-in-class treatment for ITP.

Trials 104

Trials Protein Clinical Development Drugs 104

Roots Analysis

MAY 2, 2022

Currently, a large number of plant-based proteins are being evaluated in clinical phases of development, including vaccine candidates against COVID 19 and multiple rare therapeutic disorders. The post Plant Host Systems: A Novel Advancement in Protein Expression appeared first on Blog. Our Social Media Platform.

Protein 52

Protein Development Marketing Manufacturing 52

pharmaphorum

APRIL 28, 2022

The platform combines biochemistry, native mass spectrometry, and custom chemistry to investigate protein interactions within a cellular ecosystem, whilst filtering out the “confounding complexity” of other factors in the cell, according to the biotech. Robinson is OMass’ founder and scientific advisor.

Protein 105

Protein Drugs Development Clinical Trials 105

Pharmaceutical Technology

MAY 19, 2023

ImmunoForge will expedite the development of new drugs based on the elastin-like polypeptide (ELP) platform technology originally developed by Duke’s Professor Ashutosh Chilkoti. ImmunoForge chief technology officer Dr Jim Balance pioneered the clinical development of peptide drugs genetically fused to ELPs.

Development 130

Development Drugs Licensing Licensing 130

The Pharma Data

NOVEMBER 30, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease.

Clinical Development 52

Clinical Development Vaccine Vaccination Development 52

Pharmaceutical Technology

MARCH 1, 2023

MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Cervical Cancer. It targets 4-1BB (CD137) protein mainly expressed on activated CD4+ and CD8+ T cells, activated B cells, and natural killer (NK) cells and fibroblast activating protein (FAP) which is expressed in stroma of many tumor cells.

Protein 100

Protein Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

MARCH 1, 2023

MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Colorectal Cancer. It targets 4-1BB (CD137) protein mainly expressed on activated CD4+ and CD8+ T cells, activated B cells, and natural killer (NK) cells and fibroblast activating protein (FAP) which is expressed in stroma of many tumor cells.

Protein 100

Protein Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

OCTOBER 3, 2022

Indonesia has granted Emergency Use Authorization (EUA) for the patent-free Covid-19 vaccine, IndoVac, developed by the Texas Children’s Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine, US. A recombinant protein-based Covid-19 vaccine, IndoVac received EUA in the country as a primary shot in adult patients.

Vaccine 130

Vaccine Vaccination Development Production 130

Pharmaceutical Technology

AUGUST 17, 2022

oRNA molecules have been demonstrated to possess increased stability in vivo compared to linear mRNA and can potentially create more quantities of therapeutic proteins within the body. . By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.

RNA 147

RNA Vaccine Vaccination In-Vivo 147

Pharmaceutical Technology

FEBRUARY 19, 2023

STRO-002 is under clinical development by Sutro Biopharma and currently in Phase I for Refractory Acute Myeloid Leukemia. The company works in partnership with other pharmaceutical and biotechnology companies for pre-clinical development of novel antibody drug conjugates.

Antibody 100

Antibody Protein Clinical Development Manufacturing 100

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs).

Research 130

Research Antibody Sales Development 130

Pharmaceutical Technology

DECEMBER 6, 2022

Under a possible development and commercialisation agreement in the future for the CMV vaccine candidate discovered by the parties, Evaxion will be entitled to receive upfront and milestone payments from ExpreS 2 ion.

Vaccine 130

Vaccine Vaccination Development Immune Response 130

BioPharma Reporter

JULY 12, 2021

Antibody responses against the SARS-CoV-2 spike protein were found in 99% of volunteers after the second dose of ReiTheraâs COVID-19 vaccine candidate, according to Phase 2 preliminary data.

Vaccine 105

Vaccine Vaccination Protein Antibody 105

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.

Antibody 98

Antibody Trials Licensing Licensing 98

pharmaphorum

MARCH 23, 2022

Merck & Co’s chief medical officer and head of clinical development Dr Roy Baynes has announced his retirement from the company to take up a new role alongside his former colleague Roger Perlmutter at biotech Eikon Therapeutics. billion last year.

Clinical Development 98

Clinical Development FDA Approval Vaccine Vaccination 98

Pharmaceutical Technology

FEBRUARY 20, 2023

ABN-401 is under clinical development by Abion and currently in Phase II for Solid Tumor. It conducts research and development to develop protein drugs, antibody therapeutics to target claudin essential proteins and siRNA therapeutics, to target E6, E7 oncogenes, and others.

Protein 100

Protein Drugs Clinical Trials Clinical Trials 100

Pharmaceutical Technology

JUNE 6, 2023

The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. MRNA-0184 Overview mRNA-0184 is under development for the treatment decompensated heart failure. The therapeutic candidate consists of messenger RNA (mRNA) encoding for relaxin.

RNA 100

RNA Protein Antibody Vaccine 100

Pharmaceutical Technology

JULY 7, 2022

Often referred to as a type of gene-modified cell therapy, CAR-T cell therapies involve genetically modifying a patient’s own T cells to produce a protein that enables them to identify and kill cancer cells.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

pharmaphorum

APRIL 19, 2022

The funding will be used to continue the clinical development of lead oligonucleotide PGN-EDO51 for DMD, as well as two other oligo drugs PGN-EDODM1 for myotonic dystrophy type 1 (DM1) and PGN-EDO53, another DMD candidate. Once there, they disrupt the expression of RNA coding for disease-associated proteins.

Protein 105

Protein RNA Clinical Development Production 105

Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. The company offers a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics.

Protein 100

Protein Engineer Drugs Clinical Trials 100

The Pharma Data

JULY 22, 2021

NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The companies will equally share worldwide development costs, commercialization expenses, and profits. (Nasdaq: ARVN) and Pfizer Inc.

Protein 52

Protein Development HR Hormones 52

pharmaphorum

MAY 13, 2021

These allow the body to produce a correct version of the misfolded dystrophin protein that is the root cause of DMD. But gene therapies go one step further by inserting the dystrophin gene into the patient’s muscle tissue, in order to produce a working version of the protein that is essential for building muscles.

Gene Therapy 102

Gene Therapy Gene Trials Protein 102

pharmaphorum

JANUARY 13, 2022

Clinical trials will be needed to see if doing so can interrupt the neurodegeneration seen in Parkinson’s. Alpha-synuclein is a protein that gets misfolded and clumps together in the brains of patients with Parkinson’s and other diseases collectively known as synucleinopathies.

Antibody 98

Antibody Drugs Protein Licensing 98

pharmaphorum

MARCH 3, 2021

Developers of next-generation vaccines that work against emerging variants think that stimulating a stronger T-cell response could offer more protection, as these cells target a range of proteins on the virus and not just the “Spike” protein that is prone to mutation.

Trials 105

Trials Vaccine Vaccination Protein 105

Pharmaceutical Technology

MAY 31, 2023

ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Solid Tumor. These are developed based on Atrize platform technology. Aprea Therapeutics overview Aprea Therapeutics is a biopharmaceutical company that develops cancer therapeutics that reactivate mutant tumor suppressor protein, p53.

Production 100

Production Clinical Trials Clinical Trials Development 100

pharmaphorum

SEPTEMBER 14, 2020

It uses a weakened, non-replicating, version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 coronavirus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

Vaccine 104

Vaccine Vaccination Trials Protein 104

Pharmaceutical Technology

MARCH 23, 2023

Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics.

Licensing 147

Licensing Licensing Sales Trials 147

pharmaphorum

JANUARY 25, 2021

With over 23 world-class speakers set to share their ground-breaking research developments, straight to your home or office, this is your chance to learn from the industry’s very best, including: Mitokinin showcasing how activating PINK1 dependent mitochondrial quality control to treat Parkinson’s disease. Don’t miss out!

Development 98

Development Drugs Protein Clinical Development 98

pharmaphorum

MARCH 24, 2021

Pfizer has begun clinical development of an antiviral pill against COVID-19, which could be prescribed to patients at the first sign of infection. Protease inhibitors bind to a protein that is essential to viral reproduction and are already used to other viruses such as HIV and hepatitis C, alone and in combination with other drugs.

Clinical Trials 119

Clinical Trials Clinical Trials Trials Vaccine 119